Q3 EPS Estimates for Canopy Growth Increased by Analyst

Canopy Growth Co. (NASDAQ:CGC) – Research analysts at Atb Cap Markets raised their Q3 2025 EPS estimates for Canopy Growth in a note issued to investors on Monday, December 16th. Atb Cap Markets analyst F. Gomes now forecasts that the company will post earnings of ($0.48) per share for the quarter, up from their prior forecast of ($0.49). Atb Cap Markets currently has a “Strong Sell” rating on the stock. The consensus estimate for Canopy Growth’s current full-year earnings is ($2.38) per share. Atb Cap Markets also issued estimates for Canopy Growth’s FY2027 earnings at ($3.08) EPS, FY2028 earnings at ($14.38) EPS and FY2029 earnings at ($10.27) EPS.

Canopy Growth Stock Up 4.4 %

CGC stock opened at $2.83 on Thursday. Canopy Growth has a one year low of $2.70 and a one year high of $14.92. The stock has a market capitalization of $308.31 million, a P/E ratio of -0.57 and a beta of 0.83. The company has a 50 day moving average price of $4.06 and a two-hundred day moving average price of $5.39. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.07 and a current ratio of 1.39.

Institutional Trading of Canopy Growth

Hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC purchased a new stake in shares of Canopy Growth during the 3rd quarter valued at $1,882,000. Sassicaia Capital Advisers LLC purchased a new stake in Canopy Growth during the third quarter valued at about $54,000. Centiva Capital LP purchased a new position in shares of Canopy Growth in the 3rd quarter worth about $257,000. Financial Advocates Investment Management acquired a new position in shares of Canopy Growth in the 3rd quarter valued at about $57,000. Finally, PFG Investments LLC acquired a new stake in Canopy Growth during the 3rd quarter worth approximately $54,000. 3.33% of the stock is owned by institutional investors and hedge funds.

Canopy Growth Company Profile

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments.